Apellis Pharmaceuticals, Inc.

Home » Apellis Pharmaceuticals, Inc.

Secondary

Apellis Pharmaceuticals, Inc.

We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade

Symbol

APLS

Final Price
$30.00

Shares
5,000,000

Anticipated Date
TBD

Underwriters
Citigroup, J.P. Morgan, Cowen

To view the prospectus for Apellis Pharmaceuticals, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253